MAPK4

Across TCGA pan-cancer cohorts, MAPK4 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated MAPK4 data layer compared with 24 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher MAPK4 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated MAPK4 expression acts as an unfavorable survival marker.

LUSC, HNSC, and SKCM are the cancer types where MAPK4 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	DFS	Median	All	0.197	0.717	.001	20	view →
HNSC	OS	Median	III,IV	0.021	0.675	<.001	12	view →
SKCM	DFS	Median	IV	0.036	0.433	<.001	9	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

MAPK4–LUSC (DFS)

Open the LUSC breakdown →